Description

This CME/CE-certified activity focuses on treatment strategies for depressive symptoms in bipolar disorder. It helps mental health and primary care teams understand the risks and benefits of various treatment approaches.

Effective diagnosis and treatment of bipolar disorder is critical to optimizing patient outcomes. The duration of untreated illness is directly associated with greater symptom severity, poorer response to medication, and even suicide risk early in the course of the disorder.

This activity is part of a free series. All the activities help you effectively assess and treat bipolar disorder, depression, schizophrenia, and related conditions such as fatigue and cognitive dysfunction.

View the other activities in the series: Massachusetts General Hospital Colloquium: Common Challenges in the Treatment of Mood Disorders and Schizophrenia

Learning Objectives

By the end of this program, participants will be able to:

  • Demonstrate effective treatment strategies for depressive symptoms in bipolar disorder.
  • Summarize risks and benefits of treatments for bipolar depression.
  • Describe risk of metabolic syndrome in the treatment of bipolar disorder.

Target Audience

This program is intended for:

  • Psychiatrists
  • Psychologists
  • Primary Care, Internal, and Family Care Physicians
  • Nurses
  • Allied Healthcare Professionals

Faculty

  • Thomas P. Hackett, MD, Endowed Chair in Psychiatry at MGH,
    Director, Bipolar Clinic and Research Program,
    Associate Director, Depression Clinical and Research Program,
    Director, Training and Education, MGH Research Institute,
    Massachusetts General Hospital,
    Professor of Psychiatry, Harvard Medical School

Educational Support

This program has received support in the form of educational grants from the following companies:

  • Janssen Global Services, LLC
  • Sunovion Pharmaceuticals, Inc.
  • Takeda Pharmaceuticals International, Inc.

CME Information

Release Date:October 15, 2014
Expiration Date:October 15, 2017

Date of last review:Robert Althoff, MD, on November 29, 2016

To receive credit for this activity, you must view the presentation and complete the pre test, post test, and evaluation.

CREDIT

TYPE

ACCREDITATION STATEMENT

DESIGNATION STATEMENT

1.00

AMA PRACategory
1 Credit
TM

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this enduring material for a maximum of 1.00AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

1.00

Psychologists CE Credit

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.

This offering meets the criteria for 1.00 continuing education credit for psychologists.

1.00

self-claim

Other Professions

Other Providers can claim a Participation Certificate upon successful completion of this course.

Participation Certificates will specify the title, location, type of activity, date of activity, and number ofAMA PRA Category 1 CreditsTMassociated with the activity. Providers should check with their regulatory agencies to determine ways in whichAMA PRA Category 1 CreditsTMmay or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.


Faculty Disclosure Statement

It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.


Resolution of Conflicts of Interest (COI)

McLean Hospital has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public, McLean Hospital has resolved the conflict by External Content Review.


Planner Disclosures

The following planners and/or their spouse/partner have reported no relevant financial relationship with a commercial interest.

Tristan L. Gorrindo, MD, Reviewer
Jane Pimental, MPH

The following planners and/or their spouse/partner have reported a relevant financial relationship with a commercial interest.

Michael Hirsch, MD, Reviewer
Honoraria for writing: UpToDate

Susan E. Sprich, PhD
Royalties: Oxford University Press (for co-authoring treatment manual and client workbook), Springer (for editing book)


Speaker Disclosures

The following speakers and/or their spouse/partner have reported a relevant financial relationship with a commercial interest.

Andrew A. Nierenberg, MD
Consultant: Abbott Laboratories, American Psychiatric Association, Appliance Computing Inc. (Mindsite), Basliea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaissance, Genetech, GlaxoSmithKline, Hoffman LaRoche, Infomedic, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, Naurex, Novartis, PamLabs, Pfizer, PGx Health, Ridge Diagnostics Shire, Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept, and Teva; consulted through the MGH Clinical Trials Network and Institute (CTNI) for Astra Zeneca, Brain Cells, Inc, Dianippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering-Plough, Targacept, Takeda/Lundbeck Pharmaceuticals

Grants/Research support: American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, Wyeth-Ayerst

Honoraria: Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, International Society for Bipolar Disorder, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing,Wolters Klower Publishing

Stock: Appliance Computing, Inc. (MindSite); Brain Cells, Inc., Medavante

Copyrights: Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI).


Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy

Please clickhereto review our privacy policy.